BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate and Portfolio Updates
TEL AVIV, Israel, Nov. 15, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today reported third quarter financial results and recent corporate and portfolio updates.
- "Additionally, working with our collaborators, we advanced motixafortide development programs for pancreatic cancer, reflecting motixafortide's potential broad clinical utility.
- Finally, we anticipate sharing data from the Phase 1/2a trial of our solid tumor investigational immunotherapy AGI-134 prior to year-end.
- A dial-in replay of the call will be available untilNovember 17, 2022; please dial +1-888-295-2634 from the US or +972-3-925-5903 internationally.
- BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.